Amsterdam-based Philips presented data from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial at the 2021 New Cardiovascular Horizons Conference, according to a news release.
Data presented by co-principal investigator Dr. George Adams, an interventional cardiologist at Rex Hospital (University of North Carolina, Chapel Hill), demonstrated a sustained treatment effect and a positive impact on quality of life for patients with peripheral artery disease (PAD) and critical limb ischemia (CLI) treated with the Tack dissection repair device, which Philips acquired when it bought Intact Vascular for $275 million in August 2020.
Tack is meant to repair peripheral arterial dissections following balloon angioplasty. The idea is to optimize the treatment of dissections in patients with PAD and CLI. The study found that Tack provided 73.6% of patients freedom from clinically-driven target lesion revascularization at two years, with no requirement for a repeat procedure for the treated artery segment in that chunk of patients.
In the CLI patient population, which proves to be more complex and typically associated with high rates of amputation and mortality, data showed 94.7% target limb salvage.